Available Online: Medical Device Non-Dilutive Funding: Trends & Opportunities

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.

View Slide Deck

Available Online: Non-Dilutive Funding for Non-US Applicants

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

View Slide Deck

Available Online: Non-Dilutive Funding Opportunities for CNS/PNS Related R&D

Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.

In this webinar, we discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.

View Slide Deck

 

Available Online: Non-Dilutive Funding Opportunities Beyond the SBIR

In order to maximize your funding potential, all sources of funding must be considered, including the less traditional ones.

The NIH’s R21 mechanism aims to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas the R01 mechanism is more suitable for longer programs of up to 5 years, totaling close to $3,000,000. Other agencies such as the Department of Defense, BARDA, FDA, and NSF also have awards for research in the life sciences.

In this webinar, we share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.

View Slide Deck

Available Online: Introduction to the SBIR and STTR Funding Mechanisms

SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics.

SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.

In this webinar, we discuss process for applying, guidelines, key success components and insight into increasing chances for award.

View Slide Deck

Available Online: Non-Dilutive Funding Opportunities for Clinical Reseach Webinar

Every year, US-based non-dilutive sources of funding award billions of dollars towards clinical stage research in the Life Sciences.

Funding is available for clinical stage funding across scientific fields including Infectious Diseases, Neurosciences, Cardiovascular, and many more. These funds come from multiple Institutes within the NIH, such as NIAID, NIAMS, NIDDK, from BARDA, and from the DOD.

In this webinar, we discuss the process for applying, guidelines, key success components and insight into increasing chances for award.

 

View Slide Deck

Available Online: Non-Dilutive Funding Opportunities for Pre-Clinical Reseach Webinar

Every year, US-based non-dilutive sources of funding award billions of dollars towards pre-clinical stage research in the Life Sciences.

Funding is available for pre-clinical research across scientific fields including Infectious Diseases, Oncology, Neurosciences, and many more. These funds come from Institutes within the NIH, such as NIAID, NCI, NINDS, the NSF, the DoD, and private foundations. The NIH alone annually funds over $15B to pre-clinical stage R&D in the life sciences.

In this webinar we discuss the process for applying, guidelines, key success components, and insight into increasing chances for award.

View Slide Deck

Available Online: Non-Dilutive Funding Opportunities for Cancer R&D Webinar

NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.

In this webinar, we discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for life science organizations.

View Slide Deck

Available Online: Biodefense and Infectious Diseases Funding Opportunities Webinar

The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc., this is a funding force no one in the field can afford to ignore.

In this webinar, we introduce you to Biodefense and Infectious Diseases sources of funding such as NIAID, DTRA, DARPA, US Army, and BARDA, and give examples of current open solicitations. We discuss the process for applying, major challenges, and how to maximize your chances for award.

 

View Slide Deck

Available Online: Introduction to SBIR and STTR Funding Opportunities Webinar

Opening FreeMind’s 2017 webinar series is an introduction to the SBIR and STTR mechanisms which account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics.

SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.

In this webinar we discussed process for applying, guidelines, key success components and insight into increasing chances for award.

 

View slide deck